文献速递核素与放射性配体治疗神经核医学

[177Lu]Lu-DOTATATE治疗难治性脑膜瘤:疗效相关因素与初始肿瘤剂量学数据

[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-22

仅既往系统治疗是PFS-6的危险因素(p≤0.05),且影响肿瘤生长速率(TGR)(p<0.01)。无既往系统治疗者PFS-6为67%(8/12),而有既往系统治疗者为0%。

要点

  • 既往系统治疗是难治性脑膜瘤[177Lu]Lu-DOTATATE治疗后PFS-6的唯一危险因素。
  • 无既往系统治疗者PFS-6达67%,有既往系统治疗者为0%。
  • 肿瘤吸收剂量与TGR变化无关(总体p=0.10,无既往治疗者p=0.72)。

核心结论

  • [177Lu]Lu-DOTATATE对无既往系统治疗的难治性脑膜瘤有效,即使肿瘤吸收剂量相对较低。
  • 建议在难治性脑膜瘤治疗疗程中尽早使用[177Lu]Lu-DOTATATE。

研究设计与样本

  • 分析临床因素、WHO分级、既往治疗、3D-MRI体积及治疗前PET参数与PFS-6(按3D-RANO标准定义)的关联。
  • 计算MRI获得的生长速率及肿瘤吸收剂量(TAD)。

主要发现

  • 仅既往系统治疗是PFS-6的危险因素(p≤0.05),并影响TGR(4 vs. 12例,+125% vs. -107%,p<0.01)。
  • 无既往系统治疗的12例患者中PFS-6为67%(8/12),而有既往系统治疗者PFS-6为0%。
  • 总体人群(p=0.10)及无既往治疗人群(p=0.72)中,TAD与SSTR-RT前后TGR差值均无关联。

关键数值与推荐

  • PFS-6按3D-RANO标准定义。
  • 既往系统治疗包括贝伐珠单抗或奥曲肽/依维莫司联合方案。

临床怎么用

  • 对于难治性进展性脑膜瘤,若既往未接受系统治疗,可考虑尽早使用[177Lu]Lu-DOTATATE。
  • 既往系统治疗史可能提示[177Lu]Lu-DOTATATE疗效不佳,需综合评估治疗时机。

局限性

  • 肿瘤吸收剂量与疗效的关系未显示统计学关联,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses. METHODS: Patients with refractory and progressive meningiomas treated with [177Lu]Lu-DOTATATE from 2021 to 2024 were retrospectively included. Association analyses of clinical factors, WHO grade, prior therapy (surgery, radiation, systemic therapy: bevacizumab or a combination of octreotide/everolimus), 3D-MRI volume and pretreatment PET parameters with 6-month progression-free survival (PFS-6), as defined by the 3D-RANO criteria, were performed. Growth rates obtained via MRI and tumor absorbed doses (TAD) were also calculated. RESULTS: Sixteen patients (60 [55;68] years old) underwent 4 [2;4] cycles of [177Lu]Lu-DOTATATE, with a TAD/cycle of 0.45 [0.30;0.83] Gy/GBq/cycle. Only prior systemic therapy was found as a risk factor for PFS-6 (p ≤ 0.05), with an impact on tumor growth rate (TGR) (4 vs. 12 patients, + 125% vs. -107%, p < 0.01). For the 12 patients without any prior systemic therapy, the PFS-6 was 67% (8/12 patients) whereas it was 0% in the other group, those with prior systemic therapy. No associations between the TAD and difference in the TGR before/after SSTR-RT were observed in the overall population (p = 0.10) or in the population of patients without any prior therapy (p = 0.72). CONCLUSION: [177Lu]Lu-DOTATATE appears effective in refractory meningiomas with no prior systemic therapy, even if the TADs are relatively low. [177Lu]Lu-DOTATATE should be proposed as early as possible in the treatment course of refractory meningiomas.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Boursier C, Zaragori T, Garabedian N, et al. [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. Eur J Nucl Med Mol Imaging. 2025. PMID: 40982021. doi:10.1007/s00259-025-07555-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。